Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix completed enrollment of 350 patients in the Phase 3 BiPASS study evaluating Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting. The company has aligned with the FDA on a New Drug Application pathway that, if approved, would support reimbursement as a new product and broaden access to PSMA-PET imaging.
Key figures
- Drug Name
- Illuccix, Gozellix
- Phase Of Trial
- Phase 3
- Patients enrolled
- 350
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.